Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 50 years~Exclusion Criteria:~1. Subjects with a current history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, psychiatric, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either subject safety or the results of the trial.~2. Subjects with epilepsy or a history of seizures~3. Systolic supine blood pressure ≥130 mmHg and/or supine diastolic blood pressure ≥80 mmHg at Screening or Day -1, or orthostatic hypotension at Screening or Day -1.~4. Subjects with a history of hypersensitivity to any dopamine-blocker medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Active Comparator: Group 1 Period 1: 0.5mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 1 Period 2:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 1 Period 3:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 1:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 2:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 2 Period 3:TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution
- Active Comparator: Group 3: TBD mg CVL-936 (Type: ACTIVE_COMPARATOR): Oral suspension/solution
- Placebo Comparator: Group 3: TBD mg Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo; Oral suspension/solution

Based on this trial design, predict the completion outcome and termination type (if applicable).